GMAB Stock Forecast & Price Target

Genmab's recent report indicates that DARZALEX's worldwide net sales reached $3.9 billion in 4Q25, exceeding prior estimates and reflecting a robust growth trajectory, particularly in the U.S. market, where sales amounted to $2.3 billion. The company's estimated royalty from DARZALEX for 4Q25 has been revised upward to $722 million, bolstered by its strong financial performance and a solid balance sheet, positioning Genmab favorably amid industry volatility. Furthermore, Genmab's diverse pipeline of antibody therapeutics, combined with near- and medium-term clinical data catalysts, enhances its prospects for sustained growth and profitability in the oncology sector.

Genmab faces significant risks that could adversely impact its financial performance and stock outlook, including the prospect of slowing sales for its leading product, Darzalex, and potential failures in clinical testing of other pipeline agents, notably Epcoritamab, which recently reported negative trial results. The lowered probabilities of Epcoritamab's approval in key lymphoma settings further heighten concerns about its market penetration and overall revenue trajectory. Additional factors such as currency fluctuations and long-term dilution risk may exacerbate these vulnerabilities, contributing to a pessimistic view on Genmab's stock valuation.